Wecome Pharmaceutical Co Ltd Total Assets

Latest as of September 2025: CN¥1.49 Billion CNY ≈ $217.74 Million USD

Wecome Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Wecome Pharmaceutical Co Ltd (300878) holds total assets worth CN¥1.49 Billion CNY (≈ $217.74 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Wecome Pharmaceutical Co Ltd stock valuation for the company's overall valuation and market capitalisation.

Total Assets of Wecome Pharmaceutical Co Ltd (2013–2024)

Total assets of Wecome Pharmaceutical Co Ltd from 2013 to 2024. This chart illustrates how Wecome Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Wecome Pharmaceutical Co Ltd share price for real-time trading data and today's change.

Wecome Pharmaceutical Co Ltd - Asset Composition Analysis

Wecome Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)

Wecome Pharmaceutical Co Ltd total assets breakdown as of December 2024. Wecome Pharmaceutical Co Ltd's total assets of CN¥1.49 Billion consist of 37.3% current assets and 62.7% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	15.4%
Accounts Receivable	CN¥217.87 Million	13.2%
Inventory	CN¥118.32 Million	7.2%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥33.59 Million	2.0%
Goodwill	CN¥10.97 Million	0.7%

Asset Composition Trend (2013–2024)

This chart illustrates how Wecome Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Wecome Pharmaceutical Co Ltd to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Wecome Pharmaceutical Co Ltd's current assets represent 37.3% of total assets in 2024, a decrease from 61.5% in 2013.
Cash Position: Cash and equivalents constituted 15.4% of total assets in 2024, down from 28.5% in 2013.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2013.
Asset Diversification: The largest asset category is accounts receivable at 13.2% of total assets.

Wecome Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Wecome Pharmaceutical Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	USA	$1.26 Billion
Verona Pharma plc F:I9SA	Germany	€572.87 Million
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	USA	$641.76 Million
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	China	CN¥37.46 Billion
Metsera, Inc. Common Stock NASDAQ:MTSR	USA	$639.66 Million
Beijing Tiantan Biological Products Corp Ltd SHG:600161	China	CN¥16.55 Billion
Bavarian Nordic CO:BAVA	Denmark	Dkr14.95 Billion
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥4.66 Billion

Wecome Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.34	5.16	4.67
Quick Ratio	1.97	4.45	4.29
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥305.01 Million	CN¥635.79 Million	CN¥784.97 Million

Wecome Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Wecome Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	5.05
Latest Market Cap to Assets Ratio	0.36
Asset Growth Rate (YoY)	-19.3%
Total Assets	CN¥1.65 Billion
Market Capitalization	$593.88 Million USD

Valuation Analysis

Below Book Valuation: The market values Wecome Pharmaceutical Co Ltd's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Wecome Pharmaceutical Co Ltd's assets decreased by 19.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Wecome Pharmaceutical Co Ltd (2013–2024)

The table below shows the annual total assets of Wecome Pharmaceutical Co Ltd from 2013 to 2024.

Year	Total Assets	Change
2024-12-31	CN¥1.65 Billion ≈ $241.79 Million	-19.27%
2023-12-31	CN¥2.05 Billion ≈ $299.49 Million	+6.94%
2022-12-31	CN¥1.91 Billion ≈ $280.05 Million	+13.02%
2021-12-31	CN¥1.69 Billion ≈ $247.78 Million	+3.96%
2020-12-31	CN¥1.63 Billion ≈ $238.34 Million	+85.96%
2019-12-31	CN¥875.87 Million ≈ $128.17 Million	+36.62%
2018-12-31	CN¥641.12 Million ≈ $93.82 Million	+33.64%
2017-12-31	CN¥479.74 Million ≈ $70.20 Million	+52.23%
2016-12-31	CN¥315.14 Million ≈ $46.12 Million	+42.03%
2015-12-31	CN¥221.89 Million ≈ $32.47 Million	+28.23%
2014-12-31	CN¥173.04 Million ≈ $25.32 Million	+61.53%
2013-12-31	CN¥107.13 Million ≈ $15.68 Million	--

About Wecome Pharmaceutical Co Ltd

SHE:300878 China Biotechnology

Market Cap

$593.88 Million

CN¥4.06 Billion CNY

Market Cap Rank

#11057 Global

#3014 in China

Share Price

CN¥28.03

Change (1 day)

+0.94%

52-Week Range

CN¥20.68 - CN¥39.45

All Time High

CN¥52.21